Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26/26/26	$0.3841	-7.04%	3,80,486
25/26/25	$0.4132	-4.48%	3,25,527
24/26/24	$0.4326	-3.80%	3,55,415
21/26/21	$0.4497	-4.68%	2,15,140
20/26/20	$0.4718	-0.49%	3,63,456

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3841USD

Average target price

1.500USD

Spread / Average Target

+290.52%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 01:30:00 27/08/2026 am IST			5-day change	1st Jan Change
0.3841 ^USD	-7.04%		-18.98%	-24.69%

14/08	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
12/08	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI

Market Cap	1.58Cr 1.35Cr 1.27Cr 1.16Cr 2.19Cr 150.44Cr 2.2Cr 15Cr 5.83Cr 76Cr 5.92Cr 5.79Cr 251.37Cr	P/E 2026 *	-1.67x	P/E 2027 *	-
Enterprise Value	1.58Cr 1.35Cr 1.27Cr 1.16Cr 2.19Cr 150.44Cr 2.2Cr 15Cr 5.83Cr 76Cr 5.92Cr 5.79Cr 251.37Cr	EV / Sales 2026 *	3.29x	EV / Sales 2027 *	0.92x
Free-Float	86.83%	Yield 2026 *	-	Yield 2027 *	-

14/08	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
12/08	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI
09/07	Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers	CI
19/06	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
09/06	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
02/06	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT
30/05	Scienture - Eric Sherb resigns as CFO effective May 26, 2026	RE
30/05	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026	CI
16/05	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline	RE
07/05	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing	CI
27/04	Scienture Holdings, Inc. announced that it has received $11 million in funding	CI
30/03	Scienture reports year end 2025 financial results and provides business update	RE

14/25/14	Top Midday Decliners	MT
01/23/01	EF Hutton Assumes Trxade Health at Buy With $1.25 Price Target	MT
28/23/28	Maxim Adjusts Price Target on Trxade Health to $1.75 From $2.50, Maintains Buy Rating	MT
10/22/10	Maxim Adjusts Price Target for TRxADE Health to $4 From $7, Maintains Buy Rating	MT
29/22/29	Maxim Adjusts TRxADE HEALTH's Price Target to $7 from $11, Maintains Buy Rating	MT

Scienture Holdings, Inc. Share Price

Stocks

SCNX

US80880X1046

Pharmaceuticals

Valuation: Scienture Holdings, Inc.

Chart: Scienture Holdings, Inc.

Latest news : Scienture Holdings, Inc.

Last Transcript: Scienture Holdings, Inc.

Analysts' recommendations: Scienture Holdings, Inc.

Press Releases: Scienture Holdings, Inc.

Quotes and Performance

Price Extremes

Latest insider transactions

Pharmaceuticals Wholesale

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

14/08	SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance	AQ
14/08	Scienture Holdings: Q2 Earnings Snapshot	AQ
12/08	SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray	AQ
09/07	SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers	AQ
18/06	SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide	AQ

1 day	-7.04%
1 week	-18.98%
Current month	+0.89%
1 month	+4.01%
3 months	-3.98%
6 months	-13.80%
Current year	-24.69%

1 week	0.38	0.48
1 month	0.36	0.48
Current year	0.24	0.64
1 year	0.24	2.6
3 years	0.24	13.42
5 years	0.24	13.42
10 years	0.24	13.42

Date	Insider	Type	Main position	Quantity	% Market Cap.
19/09/24	Narasimhan Mani	Conversion	Director	29,27,538	167.2839%
19/09/24	Shankar Hariharan	Conversion	Chief Executive Officer	38,53,296	220.1831%
25/07/24	Narasimhan Mani	Other	Director	57,977	4.1225%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCIENTURE HOLDINGS, INC.	-7.04%	-18.98%	-63.07%	-	1.58Cr
MCKESSON CORPORATION	-0.93%	+5.03%	+31.76%	+111.82%	10TCr
CARDINAL HEALTH, INC.	+0.20%	+1.51%	+61.64%	+172.05%	5.54TCr
SIGMA HEALTHCARE LIMITED	-7.75%	-9.66%	-7.09%	+233.76%	2.34TCr
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+1.11%	-0.37%	-15.97%	-12.04%	815.32Cr
HUADONG MEDICINE CO., LTD	+0.48%	-5.74%	-40.91%	-26.27%	712.35Cr
H. LUNDBECK A/S	-2.06%	-1.55%	+6.96%	+21.44%	644.42Cr
SINOPHARM GROUP CO. LTD.	-1.99%	-4.70%	-16.40%	-30.55%	641.74Cr
GALENICA AG	-1.26%	+1.86%	-2.72%	+19.10%	509.01Cr
SELÇUK ECZA DEPOSU TICARET VE SANAYI	+0.93%	+7.24%	+240.52%	+385.04%	387.18Cr
Average	-1.83%	-1.58%	+19.47%	+97.15%	2.21TCr
Weighted average by Cap.	-1.29%	+1.99%	+31.77%	+126.75%

	2026 *	2027 *
Net sales	47.89L 41.1L 38.58L 35.24L 66.5L 46Cr 66.82L 4.57Cr 1.77Cr 23Cr 1.8Cr 1.76Cr 76Cr	1.72Cr 1.48Cr 1.39Cr 1.27Cr 2.39Cr 164.21Cr 2.4Cr 16Cr 6.36Cr 83Cr 6.46Cr 6.32Cr 274.39Cr
Net income	-96.22L -82.59L -77.51L -70.8L -1.34Cr -92Cr -1.34Cr -9.17Cr -3.56Cr -46Cr -3.61Cr -3.53Cr -153.35Cr	1L 1L 1L 99.33T 2L 1.29Cr 2L 12.87L 5L 64.96L 5L 5L 2.15Cr
Net Debt	-	-